Tbilisi, Georgia. February 21, 2017. On February 17, 2017 the State Regulation Agency for Medical Activities, Ministry of Labour, Health and Social Affairs of Georgia granted Cromos™ Pharma approval to conduct the very first ophthalmology trial in Georgia. This international Phase III study in patients with Dry Eye Disease will enroll patients at 3 specialized ophthalmological centers.
As it has always been the case in Georgia the study approval process surpassed all expectations and took only 3 weeks after the dossier was submitted.
"Georgia has emerged as a very fruitful country for clinical research", said Tsira Jibladze, head of Georgia office of Cromos™ Pharma. "We are proud to spearhead the first ophthalmology study in Georgia and to lead the way to opening this new field of clinical research".
About Cromos™ Pharma
Cromos™ Pharma, LLC is a contract research organization (CRO) with operations in the post-Soviet space and in Eastern/Central Europe. The company provides a full spectrum of trial-related services which include clinical monitoring, regulatory approvals, medical writing, feasibility assessments, project management and warehousing. Cromos™ Pharma, LLC is a privately owned company.
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.